Valeant Completes Syndication of Incremental Term Loans
Valeant Pharmaceuticals International, Inc. announced the successful syndication of $600 million of incremental term loans under its existing senior secured credit facilities to be used to fund repayment of amounts outstanding under its existing $275 million revolving facility and for general corporate purposes, including acquisitions.
The incremental term loans will mature in 2019 and have terms that are similar to the company’s existing $600 million term loan B facility, with certain modifications. The facility closed on June 14, 2012.
Valeant Pharmaceuticals International, Inc. is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics.
Previously on abfjournal.com: